All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Priority Review Granted to Afatinib for EGFR+ Advanced NSCLC

January 15th 2013

The FDA has accepted a NDA for afatinib to treat patients with locally advanced or metastatic NSCLC who have tested positive for an EGFR mutation that has been identified through a companion diagnostic test.

Newly Approved Drugs

January 14th 2013

The FDA approved 11 new hematology-oncology drugs in 2012.

What is the New Lung Cancer Staging System?

January 12th 2013

The 7th edition TNM staging system for NSCLC is an exciting accomplishment, and will help the clinician to better understand the outcomes of lung cancer and offers an exciting advance to our specialty.

Unraveling the Layers: IDNs, ACOs, and the Future of Healthcare Integration

January 11th 2013

This recorded webinar features thought leader perspectives and key insights from HRA's newest research program - Understanding Integrated Delivery Networks.

Pap Test May Detect Ovarian and Endometrial Cancers

January 10th 2013

New research has found that Papanicolaou smear tests that collect DNA in addition to providing a routine cytologic evaluation may be able to identify mutations associated with ovarian and endometrial cancers.

Introducing the UC Davis Lung Cancer Chat Room

January 10th 2013

The UC Davis Lung Cancer Chat Room is an interactive meeting of learning and support for patients, families, friends and caregivers affected by lung cancer.

Potential Targets in Ovarian Cancer Identified

January 8th 2013

Researchers have identified the molecular basis behind two concepts in ovarian cancer that allow tumor stem cells to survive and proliferate even after treatment.

Improving Survivorship

January 8th 2013

ASCO issues recommendations for improving cancer survivorship care.

Sorafenib Improves PFS in Thyroid Cancer

January 3rd 2013

A phase III trial of sorafenib in patients with locally advanced or metastatic RAI-refractory differentiated thyroid cancer met its primary endpoint of a statistically significant improvement in PFS.

Tumor Boards

January 3rd 2013

Surprising findings about tumor board effectiveness in the VA system.

"Fiscal Cliff" Deal Averts Severe Cuts to Medicare and Cancer Research

January 2nd 2013

After wrangling between Democrats and Republicans pushed a decision beyond a year-end deadline, the federal government passed the American Taxpayer Relief Act of 2012 and averted the "fiscal cliff."

Novel Cancer Vaccine Fails To Significantly Improve Overall Survival in Lung Cancer

December 21st 2012

Results of a large phase III trial testing the efficacy of the investigational vaccine L-BLP25 in patients with advanced lung cancer found that the vaccine failed to show a statistically significant improvement in overall survival

Ponatinib Granted Early Approval for Rare Leukemias

December 14th 2012

Acting 3 months ahead of schedule, the FDA approved ponatinib for the treatment of patients with all phases of CML and Ph+ALL that is resistant or intolerant to prior TKIs.

Another Year at the Top

December 11th 2012

Nurses again rank highest in Gallup's survey on honesty and ethical standards.

FDA Approves Earlier Use of Abiraterone Acetate

December 10th 2012

The FDA has approved abiraterone acetate in combination with prednisone prior to chemotherapy for the treatment of men with metastatic castration-resistant prostate cancer.

Pancreatic Cancer

December 3rd 2012

Of the 10 most lethal cancers, it's the only one with a single digit survival rate.

FDA Approves Cabozantinib for Medullary Thyroid Cancer

November 29th 2012

The FDA approved cabozantinib, a multi-targeted tyrosine kinase inhibitor, for the treatment of metastatic medullary thyroid cancer.

Cancer-related Fatigue

November 26th 2012

Updated Cochrane review supports the benefits of aerobic exercise.

2012 Survey of RNs Released

November 13th 2012

Since last year, there has been significant improvement in career satisfaction.

FDA Grants Orphan Drug Status to Amatuximab for Malignant Pleural Mesothelioma

November 12th 2012

Amatuximab has received orphan drug status from the FDA to treat patients with malignant pleural mesothelioma, the most common form of mesothelioma.